The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Excellent TH, favorite piece in the Q+A, and what any private investor would like to hear before investing in a company. Great work Suzy and team.
We are currently working with Cenkos to build a following of interested Institutional Investors. We do
not currently intend to place new shares in an equity placing for the purposes of raising working capital,
or for the purposes of letting Institutional Investors onto the shareholder register.
Whilst on the US piece, would be good to know if the office in Boston is still operational https://www.investegate.co.uk/valirx-plc/rns/valirx-establishes-us-office-in-boston--ma/201511050700066237E/
Such a comprehensive podcast earlier, absolutely brilliant! The so went up after the q+a a few weeks back, after the podcast today I can see it going mad, 8am auction comes to mind :) Well done Suzy and team :)
Great posts Porko, gives a great synopsis of where Val are now. Totally different breed, looking forward to hearing suze tomorrow and then Monday morning action :) remember how mad it went after the last q+a interview
Thanks Adam, very interesting. I see that Astellas in partnership with Medivaiton sold Xtandi to Pfizer for $14 billion. I am by no means qualified to discuss figures and please correct me if i'm wrong, but from research Xtandi ORR of 50% and VAL-201 ORR of 54%, no brainier isn't it? :) Then begs the question, is it Astellas the Japanese pharma currently reviewing 301? You can have 201 + 301 for $20 billion, put me in control of sales + marketing for Val hahaha
Then consider rival Xtandi (Enzalutamide) ORR of 50% - https://www.cancernetwork.com/view/asco-enzalutamide-monotherapy-prostate-cancer-achieves-high-response-rate-marked-psa-decline
Interesting that support from this study was from Astellas :)
Yes come on Suz, stop ‘dilly’ dallying around and get some news out, like what I did there ;) Really liked this bit from the recent patent update rns ‘ Expanding geographical and scientific protection for these programmes provides a strong commercial background to promote to potential partners’ Let’s turn the screw now! :)
Thinking with the Swedish interest in PQE there is something substantial here. Where could the TOM MCAP be if the 10k bopd was hit? Currently sat at 9m, oil currently at $66 as well :)
Indeed, dived in yesterday through interactive investor, bit of back and forth to place through market best with an additional £49 on top of trade for the AQUIS market, but apart from that all good. Taken a punt as looking forward to seeing what the UK do in regards legalising cannibis production, and will we follow the US like normal :)
When I saw the RNS preview this morning I thought it was referring to Val 301 haha. Suze doing a little BRR media on the subject https://www.brrmedia.co.uk/broadcasts/602a52921fc46330548f9b04/valirx-extension-of-collaboration-agreement/
https://www.valirx.com/news/lsx-presention-1st-5th-february-2021